X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs DIVIS LABORATORIES - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD DIVIS LABORATORIES BIOCON LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 74.2 31.5 235.4% View Chart
P/BV x 7.0 5.5 127.9% View Chart
Dividend Yield % 0.2 0.9 19.6%  

Financials

 BIOCON LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
DIVIS LABORATORIES
Mar-17
BIOCON LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,1621,222 95.1%   
Low Rs483784 61.5%   
Sales per share (Unadj.) Rs194.6153.1 127.1%  
Earnings per share (Unadj.) Rs34.439.9 86.1%  
Cash flow per share (Unadj.) Rs48.344.6 108.2%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.11.0 12.2%  
Book value per share (Unadj.) Rs241.9201.8 119.9%  
Shares outstanding (eoy) m200.00265.47 75.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.26.6 64.5%   
Avg P/E ratio x23.925.1 95.2%  
P/CF ratio (eoy) x17.022.5 75.7%  
Price / Book Value ratio x3.45.0 68.4%  
Dividend payout %2.925.0 11.6%   
Avg Mkt Cap Rs m164,440266,266 61.8%   
No. of employees `0009.29.7 94.9%   
Total wages/salary Rs m7,4704,687 159.4%   
Avg. sales/employee Rs Th4,213.94,175.0 100.9%   
Avg. wages/employee Rs Th809.0481.5 168.0%   
Avg. net profit/employee Rs Th745.21,089.3 68.4%   
INCOME DATA
Net Sales Rs m38,91140,643 95.7%  
Other income Rs m1,571749 209.8%   
Total revenues Rs m40,48241,392 97.8%   
Gross profit Rs m9,79514,460 67.7%  
Depreciation Rs m2,7721,233 224.8%   
Interest Rs m26023 1,150.4%   
Profit before tax Rs m8,33413,953 59.7%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6163,349 48.3%   
Profit after tax Rs m6,88110,604 64.9%  
Gross profit margin %25.235.6 70.8%  
Effective tax rate %19.424.0 80.8%   
Net profit margin %17.726.1 67.8%  
BALANCE SHEET DATA
Current assets Rs m40,47740,105 100.9%   
Current liabilities Rs m16,7836,595 254.5%   
Net working cap to sales %60.982.5 73.9%  
Current ratio x2.46.1 39.7%  
Inventory Days Days60119 50.3%  
Debtors Days Days8381 102.7%  
Net fixed assets Rs m45,07319,995 225.4%   
Share capital Rs m1,000531 188.4%   
"Free" reserves Rs m47,37753,043 89.3%   
Net worth Rs m48,37753,574 90.3%   
Long term debt Rs m21,0820-   
Total assets Rs m93,94261,585 152.5%  
Interest coverage x33.1618.4 5.3%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.40.7 62.8%   
Return on assets %7.617.3 44.1%  
Return on equity %14.219.8 71.9%  
Return on capital %12.626.1 48.3%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m12,98835,384 36.7%   
Fx outflow Rs m7,89910,399 76.0%   
Net fx Rs m5,08924,985 20.4%   
CASH FLOW
From Operations Rs m6,40011,493 55.7%  
From Investments Rs m-4,985-11,372 43.8%  
From Financial Activity Rs m-1,775-93 1,906.6%  
Net Cashflow Rs m-47328 -1,665.5%  

Share Holding

Indian Promoters % 40.4 52.0 77.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.8 71.2%  
FIIs % 10.7 19.0 56.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.2 115.7%  
Shareholders   109,995 31,796 345.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare BIOCON LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; ONGC Rallies 6.3%(09:30 am)

Asian stock markets traded on a mixed note in morning trade as market participants kept an eye on political developments in the U.S. after a government shutdown began last week.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jan 22, 2018 10:03 AM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - PANACEA BIOTECH COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS